Last reviewed · How we verify
FGFR1 fusion genepositive myeloid/lymphoid neoplasm
Approved treatments
- Pemazyre · Incyte Corp
Pemazyre blocks the activity of the FGFR1 protein, which is involved in the growth and spread of cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- FGFR1 fusion genepositive myeloid/lymphoid neoplasm patent landscape — cliff calendar, originator estates, attackable patents
- FGFR1 fusion genepositive myeloid/lymphoid neoplasm treatment landscape brief
- FGFR1 fusion genepositive myeloid/lymphoid neoplasm treatment updates RSS
Frequently asked questions about FGFR1 fusion genepositive myeloid/lymphoid neoplasm
What drugs treat FGFR1 fusion genepositive myeloid/lymphoid neoplasm?
Tracked treatments include Pemazyre.
What is the treatment for FGFR1 fusion genepositive myeloid/lymphoid neoplasm?
Standard treatment for FGFR1 fusion genepositive myeloid/lymphoid neoplasm includes Pemazyre. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: FGFR1 fusion genepositive myeloid/lymphoid neoplasm patent cliff · FGFR1 fusion genepositive myeloid/lymphoid neoplasm CI report
- Treatment: Pemazyre · Incyte Corp
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing